Predictors and timing of adverse experiences during transdermal nicotine therapy

Drug Safety

Volumn 20, Issue 6, 1999, Pages 545-555

  Gourlay, Steven G ^a,b,c   Forbes, Andrew ^a   Marriner, Tracey ^a   McNeil, John J ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; ECZEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; PSORIASIS; SKIN DISEASE; SLEEP DISORDER; SMOKING CESSATION; TRANSDERMAL DRUG ADMINISTRATION; VERTIGO;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; COHORT STUDIES; COTININE; ERYTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032987470     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920060-00007     Document Type: Article

References (27)

1. 1. Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. BMJ 1993; 306: 1304-8
2. 2. Richmond RL, Harris K, de Almeida Neto A. The transdermal nicotine patch: results of a randomised placebo-controlled trial. Med J Aust 1994; 161: 130-5
3. 3. Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: one year outcome and percentage of nicotine replacement. JAMA 1994; 271: 595-600
4. 4. Gourlay SG, Forbes A, Marriner T, et al. A randomised clinical trial of a second course of transdermal nicotine therapy. BMJ 1995; 311: 363-6
5. 5. Campbell IA, Prescott RJ, Tjeder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. Respir Med 1996; 90: 47-51
6. 6. Sachs DP, Säwe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group therapy. Arch Intern Med 1993; 153: 1881-90
7. 7. Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274: 1347-52
8. 8. Transdermal nicotine study group. Transdermal nicotine for smoking cessation. JAMA 1991; 266: 3133-8
9. 9. Gourlay SG, Forbes A, Marriner T, et al. A prospective study of factors predicting smoking cessation using transdermal nicotine therapy. BMJ 1994; 309: 842-6
10. 10. Gourlay SG, Benowitz NL, Forbes A, et al. Determinants of plasma concentrations of nicotine and cotinine during smoking and transdermal nicotine treatment. Eur J Clin Pharmacol 1997; 51 (5): 407-14
11. 11. Gourlay SG, McNeil JJ. Antismoking products. Med J Aust 1990; 153: 699-707
12. 12. Dwyer CM, Forsyth A. Allergic contact dermatitis from methacrylates in a nicotine transdermal patch. Contact Dermatitis 1994; 30: 309-10
13. 13. Bircher AJ, Howald H, Rufli T. Adverse skin reactions to nicotine in a transdermal therapeutic system. Contact Dermatitis 1991; 25: 230-6
14. 14. Smith EW, Smith KA, Maibach HI, et al. The focal side effects of transdermally absorbed nicotine. Skin Pharmacol 1992; 5: 69-76
15. 15. Hogan DJ, Maibach HI. Adverse dermatological reactions to transdermal drug delivery systems. J Am Acad Dermatol 1992; 22: 811-4
16. 16. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Safety 1998; 18: 297-308
17. 17. Wolter TD, Hauri PJ, Schroeder DR, et al. Effects of 24-hr nicotine replacement on sleep and daytime activity during smoking cessation. Prev Med 1996; 25: 601-10
18. 18. Davila DG, Hurt RD, Offord KP, et al. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med 1994; 150: 469-74
19. 19. Silagy C, Mant D, Fowler G, et al. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139-42
20. 20. Benowitz, NL, Chan K, Denaro CP, et al. Stable isotope method for studying tnmsdermal drug absorption. Clin Pharm Ther 1991; 50: 286-93
21. 21. Tonnescn P, Norregaard J, Simonsen K, et al. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991; 325: 311-5
22. 22. Russell MAH, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. Br J Med 1993; 306: 1308-12
23. 23. Foulds J, Stapleton J, Hayward M, et al. Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. Arch Fam Med 1993; 2: 417-23
24. 24. Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24: 41-7
25. 25. Benowitz NL, Gourlay SG. The cardiovascular safety of nicotine: implications for nicotine replacement therapy. JACC 1997; 29: 1422-31
26. 26. Working Group for the Study of Transdermal Nicotine in Patients With Coronary Artery Disease. NRT for patients with coronary artery disease. Arch Intern Med 1994; 154: 989-95
27. 27. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335: 1792-8